Current treatment status-Did not start treatment yet - Page 19 of 37 Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Are two chemotherapies better than one in early unfavorable Hodgkin’s lymphoma?

Are two chemotherapies better than one in early unfavorable Hodgkin’s lymphoma?

Posted by on Dec 5, 2016 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the safety and effectiveness of BEACOPP chemotherapy combined with ABVD chemotherapy in patients with early unfavorable Hodgkin lymphoma. This study concluded that the combination of the two chemotherapies was more effective than ABVD alone. The combination increased the rate of negative side effects. Some background...

Read More

Examining progression to metastatic disease in men undergoing active surveillance

Examining progression to metastatic disease in men undergoing active surveillance

Posted by on Nov 30, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the incidence of metastatic disease (cancer that spreads) progression in men undergoing active surveillance. Authors concluded that active surveillance is an appropriate management of selected patients with low- to intermediate-risk prostate cancer. Only 3.1% of men progressed over an average follow-up of 6.4...

Read More

Guidelines for treatment of ipilimumab-associated hypophysitis in advanced melanoma

Guidelines for treatment of ipilimumab-associated hypophysitis in advanced melanoma

Posted by on Nov 21, 2016 in Melanoma | 0 comments

In a nutshell This study developed guidelines for the early detection and treatment of hypophysitis (HP; inflammation of the pituitary gland), a side effect of treatment with ipilimumab. Researchers suggested that these guidelines are necessary to ensure early detection and treatment of this condition to prevent associated mortality. Some background...

Read More

Optimal surgery margins in stage 2 melanomas

Optimal surgery margins in stage 2 melanomas

Posted by on Nov 14, 2016 in Melanoma | 0 comments

In a nutshell This study investigated the safe margin (the tissue removed around the tumor during surgery) for stage 2 melanomas (tumors with 1-2 mm in thickness). Researchers suggested that the safe margin during melanoma surgery is between 8 and 16 mm.  Some background The standard treatment for patients with stage 2 melanomas (tumor...

Read More

Pre-surgery chemotherapy and radiation therapy improves the outcomes of locally advanced rectal cancer

Pre-surgery chemotherapy and radiation therapy improves the outcomes of locally advanced rectal cancer

Posted by on Nov 14, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the benefits of pre-surgery chemotherapy and radiation therapy (CRT) in patients with rectal cancer and pelvic lymph node metastasis (spread of cancer). Researchers suggested that CRT may have a beneficial impact in the disease outcomes of these patients.   Some background CRT followed by surgery is the...

Read More

XELOX combined with cetuximab is an effective treatment option for metastatic colorectal cancer

XELOX combined with cetuximab is an effective treatment option for metastatic colorectal cancer

Posted by on Nov 7, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of the chemotherapy XELOX combined with cetuximab (Erbitux) as treatment for metastatic (spread to other parts of the body) colorectal cancer. Researchers suggested that this combination was effective in these patients with manageable side effects. Some background Colorectal...

Read More

Treatment options for ductal carcinoma in situ and the risk of invasive breast cancer

Treatment options for ductal carcinoma in situ and the risk of invasive breast cancer

Posted by on Oct 29, 2016 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine the effect of different treatments on the risk of developing invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). The authors concluded that there was an interaction between age and follow-up period on IBC risk and that the benefit of radiation seemed to be smaller among...

Read More

Localized surgery outcomes in early rectal cancer

Posted by on Oct 29, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the outcomes of localized surgery following chemotherapy and radiation therapy (CRT) in rectal cancer. Researchers suggested that localized surgery should only be considered after a complete response to CRT.   Some background Radical surgery or total mesorectal excision (TME; bowel and lymph nodes around...

Read More

10 years on: Comparing treatment options for localized prostate cancer

10 years on: Comparing treatment options for localized prostate cancer

Posted by on Oct 24, 2016 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of different treatment options available for localized prostate cancer. Authors reported low rates of prostate cancer-specific mortality across all treatment groups. However, surgery and radiation therapy were associated with a lower rate of disease progression and metastases compared to active...

Read More

Tumor budding as a prognostic predictive factor in colorectal cancer

Tumor budding as a prognostic predictive factor in colorectal cancer

Posted by on Oct 17, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the impact of tumor budding (when surrounding the tumor there are tumor cells released from the main tumor that can spread to other places in the body) in colorectal cancer. Researchers suggested that tumor budding is predictive of lymph node metastasis (spread to the lymph nodes), recurrence (when the cancer comes...

Read More